Joint (JYNT) to Release Earnings on Thursday

Joint (NASDAQ:JYNT) is expected to be posting its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Joint to post earnings of ($0.01) per share and revenue of $13.36 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

Joint (NASDAQ:JYNT) last posted its earnings results on Thursday, August 7th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. The company had revenue of $13.27 million for the quarter, compared to the consensus estimate of $13.32 million. Joint had a positive return on equity of 0.60% and a negative net margin of 7.02%. On average, analysts expect Joint to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Joint Trading Down 0.4%

NASDAQ:JYNT opened at $7.86 on Tuesday. The company has a market capitalization of $120.60 million, a P/E ratio of -23.82 and a beta of 1.45. Joint has a 12 month low of $7.74 and a 12 month high of $13.47. The business’s 50-day moving average is $9.41 and its 200 day moving average is $10.38.

Insider Transactions at Joint

In related news, Director Christopher M. Grandpre acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were acquired at an average cost of $10.41 per share, for a total transaction of $104,100.00. Following the completion of the transaction, the director directly owned 39,383 shares in the company, valued at approximately $409,977.03. This trade represents a 34.03% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased 34,388 shares of company stock worth $367,641 in the last quarter. Corporate insiders own 27.90% of the company’s stock.

Institutional Investors Weigh In On Joint

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in Joint by 32.3% during the second quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock valued at $86,000 after purchasing an additional 1,810 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Joint by 25.9% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company’s stock valued at $95,000 after purchasing an additional 1,698 shares during the period. Rhumbline Advisers raised its position in Joint by 25.9% during the second quarter. Rhumbline Advisers now owns 20,934 shares of the company’s stock valued at $242,000 after purchasing an additional 4,307 shares during the period. American Century Companies Inc. raised its position in Joint by 13.9% during the second quarter. American Century Companies Inc. now owns 27,572 shares of the company’s stock valued at $318,000 after purchasing an additional 3,366 shares during the period. Finally, Geode Capital Management LLC raised its position in Joint by 17.6% during the second quarter. Geode Capital Management LLC now owns 345,330 shares of the company’s stock valued at $3,986,000 after purchasing an additional 51,704 shares during the period. 76.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. B. Riley decreased their target price on Joint from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Joint in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.33.

About Joint

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.